Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

Joshua N. Gustine, Narsis Attar, Benjamin R. Puliafito, Diana D. Cirstea, Andrew R. Branagan, Andrew J. Yee, Noopur S. Raje

Open source

DOI
10.1038/s41408-026-01510-1
Published
2026-04-22
Container
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41408-026-01510-1,
  title = {Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.},
  author = {Joshua N. Gustine and Narsis Attar and Benjamin R. Puliafito and Diana D. Cirstea and Andrew R. Branagan and Andrew J. Yee and Noopur S. Raje},
  year = {2026},
  journal = {Blood Cancer Journal},
  doi = {10.1038/s41408-026-01510-1},
  url = {https://doi.org/10.1038/s41408-026-01510-1}
}

RIS

TY  - JOUR
TI  - Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.
AU  - Joshua N. Gustine
AU  - Narsis Attar
AU  - Benjamin R. Puliafito
AU  - Diana D. Cirstea
AU  - Andrew R. Branagan
AU  - Andrew J. Yee
AU  - Noopur S. Raje
PY  - 2026
JO  - Blood Cancer Journal
DO  - 10.1038/s41408-026-01510-1
UR  - https://doi.org/10.1038/s41408-026-01510-1
ER  - 

APA

Gustine, J. N., Attar, N., Puliafito, B. R., Cirstea, D. D., Branagan, A. R., Yee, A. J., & Raje, N. S. (2026). Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.. Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01510-1

Source records